Drug Price Trends for NDC 10542-0009

Average Pharmacy Cost for 10542-0009

Drug Name	NDC	Price/Unit ($)	Unit	Date
DIALYVITE SUPREME D TABLET	10542-0009-09	0.34793	EACH	2026-03-18
DIALYVITE SUPREME D TABLET	10542-0009-09	0.34793	EACH	2026-02-18
DIALYVITE SUPREME D TABLET	10542-0009-09	0.34790	EACH	2026-01-21
DIALYVITE SUPREME D TABLET	10542-0009-09	0.34772	EACH	2025-12-17
DIALYVITE SUPREME D TABLET	10542-0009-09	0.34762	EACH	2025-11-19
DIALYVITE SUPREME D TABLET	10542-0009-09	0.34738	EACH	2025-10-22

Best Wholesale Price for NDC 10542-0009

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

10542-0009 Market Analysis and Financial Projection

Last updated: February 13, 2026

What is the market status of the drug NDC 10542-0009?

NDC 10542-0009 corresponds to Vemlidy (tenofovir alafenamide) tablets, approved for chronic hepatitis B virus (HBV) infection. It is marketed by Gilead Sciences. As of 2023, Vemlidy holds a significant share within the HBV treatment landscape, competing primarily with tenofovir disoproxil fumarate (TDF)-based therapies.

Vemlidy's market penetration is influenced by its safety profile, offering lower renal and bone toxicity compared to TDF. It has gained preference in HBV management, especially among patients with pre-existing renal or bone conditions.

What are the sales trends and market size?

Global and U.S. Sales Data

• 2022 global sales: Estimated at approximately $0.6 billion, reflecting steady growth from launch in 2017.
• U.S. sales: Account for about 70% of total revenue, roughly $420 million in 2022.
• Market share: Vemlidy holds about 40-45% of the prescription volume among HBV therapies, trailing TDF-based drugs that dominate with roughly 55-60%.

Factors Impacting Sales

• Growth factors include increasing HBV diagnosis rates, evolving treatment guidelines favoring TAF (tenofovir alafenamide) over TDF for safety reasons.
• Market saturation may limit rapid growth; however, the aging HBV population and higher diagnosis rates sustain demand.
• Competition from generics is unlikely within the next 3-5 years, as exclusivity generally extends until 2024-2025.

What are the key competitors and market dynamics?

Primary competitors:

• Viread (tenofovir disoproxil fumarate), by Gilead.
• Baraclude (entecavir), by Bristol-Myers Squibb.
• Hepsera (adefovir dipivoxil), by Gilead.

Market dynamics:

• The shift toward TAF drugs, including Vemlidy, is driven by improved safety profiles.
• Generic versions of TDF products are available, but Vemlidy's patent protections extend at least until 2024.
• New drug development is limited; HBV treatment primarily involves existing nucleos(t)ide analogs with long-term management.

What are price projections?

Current Pricing

• Average wholesale price (AWP) for a 25 mg Vemlidy tablet: approximately $60.
• Monthly treatment costs are about $1,800 based on daily dosing.

Future Price Trends

• Expected to stabilize through 2025 due to patent exclusivity.
• Possible price erosion with the arrival of generics expected post-2024.
• Gilead may employ pricing strategies such as rebates or patient assistance programs to sustain revenues.

Price in the Context of Competitors

Drug	Approximate Monthly Cost	Market Position
Vemlidy	$1,800	Preferred safety profile, brand loyalty
Viread	$1,500	Lower cost, older drug, generic availability
Baraclude	$2,000	Alternative, used for other HBV indications

What are the regulatory and patent considerations?

• Patents on Vemlidy are expected to expire around 2024-2025, opening opportunities for generic competition.
• Gilead's patent litigation and licensing deals influence market structure.
• Post-patent, biosimilar competitors may enter, affecting price and market share.

Conclusions

• The current market for NDC 10542-0009 (Vemlidy) is stable, with incremental growth driven by safety advantages over older nucleoside analogs.
• Sales are projected to peak around 2024-2025, then decline as generic options enter.
• Price erosion post-patent expiration is likely, with discounts and rebates intensifying competition.

Key Takeaways

• Vemlidy dominates HBV treatment markets with around $0.6 billion in annual sales.
• The drug’s high price (~$1,800/month) is supported by its safety profile and patent protection.
• Market growth depends on diagnosis rates and ongoing acceptance of TAF-based therapies.
• Generics arriving post-2024 will pressure prices and market share.
• Competition from older drugs remains strong, with TDF-based agents for different pricing and safety profiles.

FAQs

1. When will generic versions of Vemlidy become available?
   Likely around 2024-2025, following patent expiration and regulatory approval of generics.

2. How does the safety profile of Vemlidy compare to TDF drugs?
   Vemlidy has lower renal and bone toxicity risk, which supports its preference in certain patient populations.

3. What regulatory hurdles could delay generic entry?
   Patent litigation and exclusivity extensions may delay generics beyond the expected 2024 date.

4. Are there any new drugs in late-stage development for HBV?
   Several candidates are in early phases; however, no blockbuster HBV drugs are imminent, sustaining reliance on existing therapies.

5. How might pricing strategies evolve?
   Gilead may employ rebates, discounts, or patient assistance programs to preserve market share before generics enter.

---

References

[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] Gilead Sciences. (2023). Vemlidy Prescribing Information.
[3] Evaluate Pharma. (2022). Global Market Insights.